Immatics N.V. (IMTX) has released an update.
Immatics N.V. has reported significant progress in its clinical trials, including a 50% confirmed objective response rate in a melanoma study for its ACTengine IMA203 GEN1 therapy, and partnerships with Bristol Myers Squibb and Moderna, bringing in substantial investments. The company completed a public offering of $201.5 million and, with a strong cash position of over $470 million, projects a financial runway into 2027. Immatics is preparing to initiate a Phase 2/3 trial for IMA203 GEN1 and has announced upcoming updates for its TCR Bispecifics platform in the second half of 2024.
For further insights into IMTX stock, check out TipRanks’ Stock Analysis page.
